Loading
Loading
Research Overview
Mitochondria-targeted protonophore that uncouples oxidative phosphorylation specifically in mitochondria; reduces membrane potential and increases oxygen consumption without triggering cell death or systemic hyperthermia seen with classical uncouplers like DNP.
BAM-15 is a small molecule that functions as a mitochondrial protonophore, shuttling protons across the inner mitochondrial membrane and dissipating the proton gradient used to drive ATP synthesis. By uncoupling oxidative phosphorylation from ATP production, BAM-15 forces cells to burn additional fuel to maintain cellular energy balance, increasing metabolic rate and heat production. Preclinical research has used this mechanism to study the consequences of elevated mitochondrial uncoupling in metabolic disease model systems.
In preclinical metabolic research, BAM-15 has been studied as a pharmacological tool for investigating the effects of increased energy expenditure on adipose tissue and hepatic lipid metabolism in animal models. A key feature of BAM-15 that distinguishes it from classical uncouplers such as 2,4-dinitrophenol is its reported lack of significant central nervous system penetration, which has motivated preclinical investigations of its safety profile relative to earlier uncoupling agents.
Preclinical combination studies examining BAM-15 alongside other metabolic compounds such as SLU-PP-332 have explored whether complementary mechanisms for increasing energy expenditure produce additive metabolic effects in animal models. These combination research approaches have used BAM-15 as a tool to understand how peripheral mitochondrial uncoupling interacts with transcriptional programmes governing mitochondrial biogenesis in metabolically relevant tissues.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, bam-15 (mitochondrial uncoupler) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
BAM-15 (Mitochondrial Uncoupler) research is most relevant to protocols examining:
Safe mitochondrial uncoupling research
the non-toxic alternative to DNP
Metabolic thermogenesis and energy expenditure studies
Obesity model research examining fat loss via increased oxygen consumption
Researchers studying mitochondria-selective protonophores
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
Mitochondria-targeted protonophore that uncouples oxidative phosphorylation specifically in mitochondria; reduces membrane potential and increases oxygen consumption without triggering cell death or systemic hyperthermia seen with classical uncouplers like DNP.
| Parameter | Value |
|---|---|
| Dose range | Under investigation |
| Schedule | Daily |
| Route | Subcutaneous, Oral (under study) |
| Half-life | ~Hours |
primarily preclinical
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.